Paris, May 2018
Prescrire's response to a public consultation by the European Medicines Agency on non-compliance with good manufacturing practice (GMP) highlighted the growing problem with supplies of medicines of major therapeutic interest, in France and also in other European countries. Drug companies must be reminded that they have not just rights but also obligations, in particular the timely delivery of orders, while fully respecting GMP.
> Download Prescrire's response (pdf, 142 Ko)
©Prescrire May 2018
Share |
 |
 |